EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapy

Mohammed Qarmout, Yasir Alsaraf, Qasim Alameri, Grace Brannan, Susan Lyons

Archives of Breast Cancer · 25.07.2026 · 13 (3)

DOI: 10.32768/abc.7619204835-174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Breast Cancer, online erschienen am 25.07.2026. Verfasst von Mohammed Qarmout und 4 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurately identifying patients with estrogen receptor (ER)+HER2− breast cancer benefiting from extended endocrine therapy (EET) remains challenging. While the Clinical Treatment Score at 5 Years (CTS5) and the Breast Cancer Index (BCI) are established tools for assessing late recurrence risk, their comparative utility in real-world practice is underexplored. The CTS5 only provides prognostic data, but the BCI provides both prognostic and predictive data.

Methods

We conducted a retrospective study evaluating concordance between the CTS5 and the BCI in patients with early-stage ER+HER2− disease who completed 5 years of adjuvant endocrine therapy (2023–2024). Intertest reliability was quantified using descriptive statistics and the Cohen κ coefficient.

Results

In 59 patients, overall concordance was 37.3%. Agreement was highest in low-risk, grade 1 tumors (54.5%). Discordance was significant in those with higher-risk features. Notably, 32.2% were CTS5 “intermediate,” where the BCI offered binary guidance. Sankey diagrams revealed that 57.1% of patients with BCI-recommended EET were CTS5 low risk. The Cohen κ coefficient was 0.067 (95% CI, −0.156 to 0.290; P = 0.56).

Conclusion

Our study showed limited CTS5 and BCI concordance rates in clearly low-risk populations and non-statistically significant results overall. These limited findings warrant further exploration of integrating genomic assays to optimize therapy duration.

Zitieren

APA

Qarmout, M., Alsaraf, Y., Alameri, Q., Brannan, G., & Lyons, S. (2026). Real-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapy. Archives of Breast Cancer, 13(3). https://doi.org/10.32768/abc.7619204835-174

Vancouver

Qarmout M, Alsaraf Y, Alameri Q, Brannan G, Lyons S. Real-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapy. Archives of Breast Cancer. 2026;13(3). doi:10.32768/abc.7619204835-174

BibTeX
@article{Qarmout2026,
  author = {Qarmout, Mohammed and Alsaraf, Yasir and Alameri, Qasim and Brannan, Grace and Lyons, Susan},
  title = {Real-World Experience Using the Clinical Treatment Score at 5 Years (CTS5) and Breast Cancer Index (BCI) to Guide Extended Adjuvant Endocrine Therapy},
  journal = {Archives of Breast Cancer},
  year = {2026},
  volume = {13},
  number = {3},
  doi = {10.32768/abc.7619204835-174}
}
Kostenlos starten →